Evidence supporting the use of: Epigallocatechin gallate
For the health condition: Rheumatoid Arthritis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Epigallocatechin gallate (EGCG), a major polyphenol found in green tea, has been investigated for its potential effects in supporting or treating rheumatoid arthritis (RA). The evidence base is limited but emerging, and primarily preclinical. Several in vitro studies and animal models suggest that EGCG exhibits anti-inflammatory and immunomodulatory properties. It appears to inhibit the production of pro-inflammatory cytokines such as TNF-alpha, IL-1β, and IL-6, as well as reducing the activity of matrix metalloproteinases that contribute to joint destruction in RA. For example, a 2014 study in Arthritis & Rheumatology demonstrated that EGCG suppressed key inflammatory pathways (NF-κB and MAPK) in synovial fibroblasts from RA patients. Animal model studies have shown that EGCG administration can reduce joint swelling and histological disease severity.

However, clinical evidence in humans is minimal. There are no large-scale randomized controlled trials demonstrating efficacy or safety of EGCG as a treatment for RA in patients. Most available data are from cell culture or animal experiments. Thus, while there is a scientific rationale and some preclinical support for EGCG's use in RA, the overall quality of evidence is low (rated 2/5), and it should not be considered a proven or primary therapy. More rigorous human studies are needed to establish its therapeutic potential and safety profile in this context.

More about Epigallocatechin gallate
More about Rheumatoid Arthritis

Products containing Epigallocatechin gallate

We currently have no products on Vitabase that contain this ingredient.